Phase IIIPeptide
Compound 61418
Formula Pending
Molecular Mass
N/A
CAS Registry
AUTO-061418
Risk Class
MODERATE
Last Audit
Jan 30, 2108
Research Abstract
Peptide candidate engineered for oncology adjuvant initiatives with automated dossier coverage.
Compound 61418 is a peptide asset inside peptide innovation track initiatives, optimized for oncology adjuvant and inflammation control.
The dossier currently sits in phase iii with a moderate risk rating, meaning it is requires layered oversight with metabolic labs.
Supply records cite CAS AUTO-061418 with updates logged 2108-01-30.
Acquisition Protocol
Authorized research personnel may request deployment of this compound for laboratory analysis.
Primary Vectors
Oncology adjuvantInflammation control
Nomenclature
CX-61418Peptide Program 61418
Reference Material
- [1] Anubis Compound Registry • CAS AUTO-061418
- [2] Operations Pulse • Peptide innovation track
- [3] Risk Governance Ledger • MODERATE clearance for COMPOUND-61418